Monte Rosa Therapeutics Inc

General ticker "GLUE" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $704.9M

Monte Rosa Therapeutics Inc follows the US Stock Market performance with the rate: 30.6%.

Estimated limits based on current volatility of 4.2%: low 6.56$, high 7.13$

Factors to consider:

  • Price in estimated range
  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [3.14$, 7.31$]
  • 2024-12-30 to 2025-12-30 estimated range: [3.50$, 7.83$]

Financial Metrics affecting the GLUE estimates:

  • Negative: Non-GAAP EPS, $ of -2.64 <= 0.10
  • Negative: Operating profit margin, % of -100 <= 1.03
  • Negative: Operating cash flow per share per price, % of -16.76 <= 2.35
  • Negative: negative Net income
  • Positive: Industry inventory ratio change (median), % of 0 <= 0

Similar symbols

Short-term GLUE quotes

Long-term GLUE plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $72.88MM $112.38MM $143.31MM
Operating Income $-72.88MM $-112.38MM $-143.31MM
Non-Operating Income $0.05MM $3.88MM $8.30MM
Interest Expense $0.00MM $3.76MM $0.00MM
R&D Expense $57.16MM $85.06MM $111.27MM
Income(Loss) $-72.83MM $-108.50MM $-135.01MM
Taxes $0.00MM $-3.88MM $0.34MM
Profit(Loss) $-72.83MM $-104.62MM $-135.35MM
Stockholders Equity $347.51MM $271.41MM $179.25MM
Inventory $0.00MM $0.96MM $0.00MM
Assets $366.33MM $342.39MM $303.75MM
Operating Cash Flow $-59.36MM $-92.47MM $-43.80MM
Capital expenditure $9.73MM $12.91MM $19.04MM
Investing Cash Flow $-9.65MM $-219.22MM $88.80MM
Financing Cash Flow $377.56MM $20.47MM $27.49MM
Earnings Per Share* $-1.55 $-2.22 $-2.63

* EPS are Split Adjusted, recent splits may be reflected with a delay.